Vontobel Holding Ltd. Buys 5,109 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Vontobel Holding Ltd. lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 88.6% during the fourth quarter, HoldingsChannel reports. The firm owned 10,875 shares of the biopharmaceutical company’s stock after purchasing an additional 5,109 shares during the period. Vontobel Holding Ltd.’s holdings in Alnylam Pharmaceuticals were worth $2,082,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in ALNY. Harbor Capital Advisors Inc. lifted its stake in Alnylam Pharmaceuticals by 1.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after acquiring an additional 51 shares during the period. Captrust Financial Advisors lifted its stake in Alnylam Pharmaceuticals by 4.3% in the second quarter. Captrust Financial Advisors now owns 1,285 shares of the biopharmaceutical company’s stock worth $187,000 after acquiring an additional 53 shares during the period. EP Wealth Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 6.4% in the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 71 shares during the period. CIBC Asset Management Inc lifted its stake in Alnylam Pharmaceuticals by 2.0% in the first quarter. CIBC Asset Management Inc now owns 4,191 shares of the biopharmaceutical company’s stock worth $840,000 after acquiring an additional 84 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its stake in Alnylam Pharmaceuticals by 2.1% in the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock worth $800,000 after acquiring an additional 93 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 0.1 %

ALNY stock opened at $145.16 on Friday. The firm has a 50 day moving average of $152.07 and a 200 day moving average of $167.03. The stock has a market capitalization of $18.28 billion, a PE ratio of -40.78 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52 week low of $143.52 and a 52 week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the business earned ($1.68) earnings per share. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on ALNY shares. The Goldman Sachs Group lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $230.00 to $173.00 in a research note on Friday, February 16th. Citigroup lowered their price objective on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Needham & Company LLC reissued a “buy” rating and set a $200.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, April 13th. Finally, Chardan Capital decreased their price target on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Eight analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $216.12.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.